GUBRA.CO in “GLP-1 Eats Everything”
Gubra A/S
Gubra develops peptide-based obesity drugs, including a long-acting amylin analogue partnered with AbbVie that could complement GLP-1 therapy.
GUBRA.CO impact map — “GLP-1 Eats Everything”
How this story travels from the headline to GUBRA.CO’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading GUBRA.CO impact map…
Price history, marked with story events
Aug 25, 2025 – Aug 26, 2026 · 250 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — Gubra develops peptide-based obesity drugs, including a long-acting amylin analogue partnered with AbbVie that could complement GLP-1 therapy.
Read the full GLP-1 Eats Everything story